AGILE THERAPEUTICS INC - AGRX STOCK NEWS

Agile Therapeutics, Inc. (Nasdaq: AGRX) has announced a leadership reorganization to enhance its growth strategy for Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. Effective November 1, 2022, Amy Welsh will become Chief Commercial Officer. The company also appointed Geoffrey P. Gilmore as Chief Administrative Officer. Meanwhile, James P. Tursi, M.D. has resigned from the board of directors to focus on his role at Endo Pharmaceuticals. The leadership changes aim to create operational efficiencies and support Twirla’s market growth initiatives.

Agile Therapeutics, Inc. (Nasdaq: AGRX) announced that Chairman and CEO Al Altomari and VP of Marketing Amy Welsh will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY, from September 12-14, 2022. Their presentation is scheduled for September 13, 2022, from 10:00-10:30 am ET. A webcast of the presentation will be available on the company’s investor relations page, with replays accessible for 30 days.

Agile is committed to women's healthcare, offering innovative contraceptive solutions like Twirla®.

Agile Therapeutics (Nasdaq: AGRX) reported significant growth in Twirla demand and a reduction in operating expenses for Q2 2022. Twirla demand grew 27% and revenue increased 75% year-over-year, reaching $2.1 million. Operating expenses decreased by 28% to $11.3 million compared to Q1 2022. The company expects to maintain these lower expenses in the second half of 2022. Additionally, Agile signed a product supply agreement with Nurx, enhancing access to Twirla. As of June 30, 2022, cash reserves stood at $13 million, sufficient to fund operations through the end of 2022.

Agile Therapeutics (Nasdaq: AGRX) will report its second quarter 2022 financial results after market close on August 11, 2022. The company will host a live conference call at 4:30 p.m. ET to discuss these results and provide a business update. Interested parties can join the call by dialing (888) 330-2454 for domestic or (240) 789-2714 for international listeners, using Conference ID 7871426. A live webcast will also be available on their investor relations page.

On July 12, 2022, Agile Therapeutics (Nasdaq: AGRX) updated its Q2 2022 guidance for Twirla demand and operating expenses. The company now anticipates Twirla demand to reach 21,000 to 21,500 cycles, reflecting a quarterly growth of 26% to 30%. This adjustment is attributed to success in both retail and non-retail channels, particularly through a partnership with Afaxys. Operating expenses are expected to be between $11.5 million and $12.5 million, below previous estimates, due to optimized sales and marketing efforts.

Agile Therapeutics (Nasdaq: AGRX) will participate in a virtual panel discussion on July 13, 2022, at 11:00 a.m. ET. The panel, titled “A Tipping Point in Women’s Health - Does the SCOTUS Outcome Change the Paradigm in Contraception?” will be moderated by Jason McCarthy from Maxim Group. CEO Al Altomari will join other industry leaders including Sabrina Martucci Johnson and Kathy Lee-Sepsick. The event will be available on Maxim's M-Vest website and archived on Agile's investor relations page from July 15-28, 2022.

Agile Therapeutics (Nasdaq: AGRX) has successfully closed an upsized public offering of 26,666,666 shares of common stock, including pre-funded warrants, at a price of $0.90 per share. The total gross proceeds from this offering are approximately $24.0 million, aimed at supporting working capital, business development, and general corporate purposes. Each share is paired with Series A-1 and A-2 warrants, both exercisable at $0.90. This follows the SEC's approval of the registration following filings made on July 1, 2022. H.C. Wainwright & Co. acted as the exclusive placement agent.

Agile Therapeutics (Nasdaq: AGRX) announced a public offering of 26,666,666 shares of common stock, priced at $0.90 each, along with warrants. The offering aims to raise approximately $24 million before fees. Each share comes with two types of warrants, both exercisable immediately. The closing is expected by July 6, 2022, subject to customary conditions. Funds will be used for working capital and business development. The offering is made under effective SEC registration statements.

Agile Therapeutics (Nasdaq: AGRX) announced that CEO Al Altomari will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, from 10:00-10:30 am ET. The conference will take place in Miami, FL, from May 23-26, 2022. The presentation will be available via live webcast on the company’s investor relations page, with a replay archived for 90 days. Agile Therapeutics focuses on women's healthcare, providing innovative contraceptive options through its proprietary Skinfusion technology.